Hemostemix IncHemostemix IncHemostemix Inc

Hemostemix Inc

No trades
See on Supercharts

HMTXF fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Hemostemix, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. The firm's, ACP-01, lead clinical stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. The company was founded by Roger Bergersen and Thomas A. Smeenk in 2006 and is headquartered in Calgary, Canada.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

HMTXF does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company